Price$16.48-0.26 (-1.55%)
01:30 PM07:45 PM
News · 26 weeks75+20%
2026-04-192026-10-11
Mix3790d
- Insider16(43%)
- SEC Filings8(22%)
- Other6(16%)
- Analyst3(8%)
- Earnings2(5%)
- Offering2(5%)
Latest news
25 items- SECSEC Form 8-K filed by Bausch + Lomb Corporation8-K - Bausch & Lomb Corp (0001860742) (Filer)
- PRBausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 GuidanceBausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company, and its parent company, Bausch Health Companies Inc. (NYSE/TSX:BHC), today announced that Bausch + Lomb Board of Directors Chairman Thomas J. Appio has been appointed interim chief executive officer, effective immediately. Appio will continue to serve as CEO of Bausch Health while assuming leadership of Bausch + Lomb. Appio was appointed chairman of the Bausch + Lomb Board of Directors in August 2026. The Board believes Appio’s deep knowledge of the business, global leadership experience and longstanding connection to Bausch + Lomb position him well to build on the company’s momentum and lead its next phase of
- ANALYSTBarclays initiated coverage on Bausch + Lomb with a new price targetBarclays initiated coverage of Bausch + Lomb with a rating of Overweight and set a new price target of $24.00
- PRBausch + Lomb Advances Novel Oral Treatment for Dry AMD Following Constructive FDA MeetingBL1243 (tonabersat) is being developed as a potential oral treatment for patients with earlier-stage dry AMD, where treatment options remain limited Clinical development program expected to begin in 2027 Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced progress in the development of BL1243 (tonabersat), an investigational oral treatment for dry age-related macular degeneration (AMD), following a constructive meeting with the U.S. Food and Drug Administration (FDA). The discussion provided greater clarity on the clinical development path for BL1243. If successfully developed and appr
- PRBausch + Lomb Will Release Third-Quarter 2026 Financial Results on Oct. 28Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its third-quarter financial results on Wednesday, Oct. 28, 2026. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call. Conference Call Details Date: Wednesday, Oct. 28, 2026 Time: 8 a.m. ET Webcast: https://www.webcaster5.com/Webcast/Page/2883/53395 Participant Event Dial-in: +1 (888) 50
- SECSEC Form 144 filed by Bausch + Lomb Corporation144 - Bausch & Lomb Corp (0001860742) (Subject)
- PRBausch + Lomb Announces European CE Mark Approval of SeeLyra™ Femtosecond LaserNext-generation platform provides precision and control in laser-assisted preparation for premium cataract, LASIK flap and corneal therapeutic surgeries with live swept source OCT Compact design accommodates today’s space-constrained operating rooms Platform mobility, versatile configurations support efficiency, streamlined workflows Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced European CE Mark approval of SeeLyra, the company’s next generation femtosecond laser. One of the most compact femtosecond platforms available, SeeLyra provides surgeons precision and control when perfor
- ANALYSTLeerink Partners initiated coverage on Bausch + Lomb with a new price targetLeerink Partners initiated coverage of Bausch + Lomb with a rating of Outperform and set a new price target of $24.00
- PRBausch + Lomb Announces New Published Research on enVista Aspire™ Real World ExperienceMulticenter retrospective case series published in Ophthalmology and Therapy Results demonstrate enVista Aspire and enVista Aspire toric deliver good distance and functional intermediate vision in a majority of patients Study shows these enhanced monofocal lenses can meet digital demands modern cataract patients face This paper and other data on enVista Aspire can be found on Bausch + Lomb’s new Eye Care Professional Hub Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the publication of new research on real world experience with enVista Aspire and enVista Aspire toric intraocul
- PRMost Women Don't Recognize Dry Eye as a Symptom of Perimenopause and Menopause, New Bausch + Lomb Survey FindsOnly 14% of peri-, menopausal and post-menopausal women recognize dry eye as a menopause-related symptom. 78% of women were surprised to learn that dry eye is a symptom of perimenopause or menopause. Women experiencing dry eye reported impacts on everyday activities including reading, screen use, driving and productivity. Findings underscore the need for greater awareness of the connection between menopause and eye health. Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced findings from a new survey highlighting a significant awareness gap around dry eye and its association with p
- PRBausch + Lomb Advancing Two First-in-Class Eye Health Therapies Based on Trial ResultsDual-action eye drop targeting both evaporative and inflammatory dry eye disease moving to Phase 3 Positive Phase 1b results for ocular surface pain candidate validate TRPV1 antagonist approach and strengthen confidence in ongoing Phase 2 study Combined potential peak sales exceeding $2 billion assuming successful development and commercialization1 Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that two of its pharmaceutical pipeline assets – both first-in-class treatments – will advance to new trials based on recent clinical results. "Helping people see better to live better s
- INSIDERDirector Trebbi Barbara was granted 11,776 shares (SEC Form 4)4 - Bausch & Lomb Corp (0001860742) (Issuer)
- INSIDERSEC Form 3 filed by new insider Trebbi Barbara3 - Bausch & Lomb Corp (0001860742) (Issuer)
- INSIDERDirector Paul Laurence E was granted 11,776 shares (SEC Form 4)4 - Bausch & Lomb Corp (0001860742) (Issuer)
- INSIDERSEC Form 3 filed by new insider Paul Laurence E3 - Bausch & Lomb Corp (0001860742) (Issuer)
- INSIDERDirector Chersi Robert J was granted 11,776 shares (SEC Form 4)4 - Bausch & Lomb Corp (0001860742) (Issuer)
- INSIDERSEC Form 3 filed by new insider Chersi Robert J3 - Bausch & Lomb Corp (0001860742) (Issuer)
- INSIDERNew insider Appio Thomas claimed ownership of 27,583 shares (SEC Form 3)3 - Bausch & Lomb Corp (0001860742) (Issuer)
- INSIDERSVP, Controller and CAO Munsch Frederick sold $887,662 worth of shares (52,900 units at $16.78), decreasing direct ownership by 54% to 45,831 units (SEC Form 4)4 - Bausch & Lomb Corp (0001860742) (Issuer)
- SECAmendment: SEC Form 8-K/A filed by Bausch + Lomb Corporation8-K/A - Bausch & Lomb Corp (0001860742) (Filer)
- INSIDERDirector Von Eschenbach Andrew C. sold $306,708 worth of shares (18,559 units at $16.53), decreasing direct ownership by 23% to 63,733 units (SEC Form 4)4 - Bausch & Lomb Corp (0001860742) (Issuer)
- SECSEC Form 144 filed by Bausch + Lomb Corporation144 - Bausch & Lomb Corp (0001860742) (Subject)
- INSIDERPresident, GPIC Stewart Andrew J. was granted 16,778 shares, increasing direct ownership by 19% to 103,211 units (SEC Form 4)4 - Bausch & Lomb Corp (0001860742) (Issuer)
- INSIDERSVP, Controller and CAO Munsch Frederick was granted 9,091 shares, increasing direct ownership by 10% to 98,731 units (SEC Form 4)4 - Bausch & Lomb Corp (0001860742) (Issuer)
- INSIDEREVP of R&D and CMO Hashad Yehia was granted 20,973 shares, increasing direct ownership by 13% to 187,350 units (SEC Form 4)4 - Bausch & Lomb Corp (0001860742) (Issuer)
BLCO FAQ
7 questionsWhat does Bausch + Lomb Corporation do?
Bausch + Lomb Corporation operates as an eye health company in Canada and internationally. It operates through three segments: Vision Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that cover the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic...Where does BLCO stock trade?
Bausch + Lomb Corporation (BLCO) is listed on NYSE.What sector and industry is BLCO in?
Bausch + Lomb Corporation operates in the Health Care sector, Ophthalmic Goods industry.When did Bausch + Lomb Corporation go public?
Bausch + Lomb Corporation (BLCO) completed its IPO in 2022.What are analysts saying about BLCO?
Bausch + Lomb Corporation has had 8 recent analyst actions on file. The most recent action was from Barclays: Overweight with a $2400.00 price target on 2026-10-07. Recent price targets range from $1500.00 to $2400.00.What companies are similar to BLCO?
Notable peers in the same industry include ALC (Alcon Inc.), COO (The Cooper Companies Inc.), WRBY (Warby Parker Inc.), EYE (National Vision Holdings Inc.), STAA (STAAR Surgical Company). Compare BLCO side-by-side with any of them on Quantisnow.How can I track BLCO on Quantisnow?
Quantisnow aggregates Bausch + Lomb Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BLCO to receive live email and push alerts on every new disclosure.